CPG10101 Combination Therapy For The Treatment Of Hepatitis C In Relapsed Hepatitis C Virus (HCV) Subjects
Status:
Completed
Trial end date:
2007-02-01
Target enrollment:
Participant gender:
Summary
1. To characterize the tolerability profile of subcutaneous (SC) CPG 10101 alone, with
pegylated interferon, ribavirin or both pegylated interferon and ribavirin when
administered weekly for twelve weeks in relapsed HCV positive subjects.
2. To assess the effect of subcutaneous (SC) CPG 10101 alone, with pegylated interferon,
ribavirin or both pegylated interferon and ribavirin on serum Hepatitis C Virus (HCV)
RNA concentrations